Advancements in diagnosis and management of paroxysmal nocturnal hemoglobinuria - review.
- Author:
Ying-Xin SUN
1
;
Guang-Sheng HE
Author Information
1. Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Antibodies, Monoclonal, Humanized;
therapeutic use;
Hematopoietic Stem Cell Transplantation;
Hemoglobinuria, Paroxysmal;
diagnosis;
therapy;
Humans
- From:
Journal of Experimental Hematology
2012;20(5):1267-1271
- CountryChina
- Language:Chinese
-
Abstract:
Paroxysmal nocturnal hemoglobinuria (PNH) is a hemolytic disease of abnormally activated complement. FLAER diagnosis is a higher sensitive and specific method, which makes PNH patients to be early discovered and treated. Non-typical symptoms including thrombosis, pulmonary hypertension and chronic kidney disease in PNH have been caused increasing attention. Eculizumab monoclonal antibody has greatly improved the current treatment status of PNH. PNH can be cured thoroughly by allogeneic hematopoietic stem cell transplantation. In this article, the FLAER diagnosis, clinic symptoms and progress of treatment in patients with PNH are reviewed.
